U.S. markets closed
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • Dow 30

    35,677.02
    +73.94 (+0.21%)
     
  • Nasdaq

    15,090.20
    -125.50 (-0.82%)
     
  • Russell 2000

    2,291.27
    -4.92 (-0.21%)
     
  • Crude Oil

    83.98
    +1.48 (+1.79%)
     
  • Gold

    1,793.10
    +11.20 (+0.63%)
     
  • Silver

    24.39
    +0.22 (+0.91%)
     
  • EUR/USD

    1.1646
    +0.0015 (+0.13%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • GBP/USD

    1.3760
    -0.0036 (-0.26%)
     
  • USD/JPY

    113.4800
    -0.5080 (-0.45%)
     
  • BTC-USD

    61,397.09
    +794.94 (+1.31%)
     
  • CMC Crypto 200

    1,453.34
    -49.69 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,804.85
    +96.27 (+0.34%)
     

Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE: ZYME) presented encouraging early data on its HER2‑targeted bispecific antibody.

  • Twenty-eight patients were deemed evaluable.

  • Zymeworks’ zanidatamab, combined with one of two chemotherapy regimens, posted an overall response rate of 75% in patients with advanced gastroesophageal adenocarcinoma (GEA) who had not previously received a HER2-targeted cancer therapy.

  • The overall disease control rate (DCR) was 89%.

  • There was one complete response and 20 partial responses.

  • Meanwhile, the median duration of response was 16.4 months, with a median progression-free survival of one year across all patients. At the cutoff, 61% of patients were still in the study.

  • Zymeworks plans to pursue a Phase 3 study with the combination of zanidatamab and the chemo regimen known as CAPOX/FP.

  • The combo regime posted a response rate of 93% and DCR of 100%.

  • Zymeworks plans to launch with BeiGene Ltd (NASDAQ: BGNE) HERIZON-GEA-01 study in Q4.

  • The planned trial will test the zanidatamab-CAPOX combo with or without PD-1 inhibitor tislelizumab in a head-to-head matchup with the trastuzumab (Herceptin)-chemo standard of care in first-line advanced GEA.

  • Novartis AG (NYSE: NVS) in-licensed tislelizumab from BeiGene in North America, Europe, and Japan.

  • Price Action: ZYME stock is up 5.93% at $34.99 during the market session on the last check Thursday.

  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.